CD4 and HIV infectious disease: Leronlimab and maraviroc are monoclonal antibody and small-molecule ligands of CCR5, respectively, which are approved drugs for the treatment of HIV infection and operate by blocking CCR5-tropic HIV entry into CD4+ host cells [69,70].